The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
USA: The investigational siRNA therapy cemdisiran met both its primary and a key secondary endpoint in the phase III NIMBLE ...
Scientists have long thought that the brain knows it’s time to push the plate away almost entirely because of signaling cells ...
A new grant from the American Cancer Society (ACS) will fund research into a new strategy for targeting glioblastoma at MUSC ...
To confirm the mechanism, they administered naloxone, a drug that blocks opioid receptors. Placebo pain relief was completely ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...
Morning Overview on MSN
AstraZeneca says Ultomiris cut urine protein in late-stage kidney trial
AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...
MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial . Totality of efficacy and safety data re ...
For years, pomegranates have enjoyed a reputation as a "heart-healthy" fruit. As a cardiovascular researcher, I have often ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
Systemic lupus erythematosus (SLE) involves ongoing inflammation, tissue damage from immune complexes, and incomplete immune resolution. A key factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results